Reaction profile

The FDA adverse-event record for lack of efficacy (protozoa) - cytauxzoon feli

Name: Lack of efficacy (protozoa) - Cytauxzoon feli - FDA Animal Adverse Reaction
Creator: PlainBreed
License: https://open.fda.gov/license/

29 FDA reports name lack of efficacy (protozoa) - cytauxzoon feli, a lower-volume reaction in the CVM extract (VeDDRA 3134). Plate stamps and neighbourhood peers follow.

#2015 of 2,481
by report volume (all reactions): 29
reports citing this reaction: 48.3%
death-coded share: Cat
most-affected species

Compiled by PlainBreed

Verify with FDA CVM →

Release-over-release change

What changed in the latest FDA data snapshot

PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. Lack of efficacy (protozoa) - Cytauxzoon feli has 29 reports now versus 27 in that prior snapshot: 2 more (7.4%).

Report change: +2
Death-coded reports: +1
Death-coded share: +0.1 pts

This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.

Subscribe to Lack of efficacy (protozoa) - Cytauxzoon feli changes

FDA AER · VeDDRA plate

Code 3134 VOL-TRACE

VOL-TRACE · DEATH-HOT · LOWER-Q · PHOTO-FINISH · SPECIES-CAT · DRUG-LEAD · DESK-MID · BOOK-FULL

VOL-TRACE 29 reports
DEATH-HOT 48.3%
LOWER-Q #2015/2481
PHOTO-FINISH Application site mois…
SPECIES-CAT Cat · 29
DRUG-LEAD Fluralaner/Moxide… · 10
DESK-MID 5 breeds
BOOK-FULL 8/8 fields

Nearest volume peer: Application site moist eczema (±0 reports)

Upper-third death-coded share drives the outcome stamps on this plate; volume band, corpus rank, and co-report peers follow. Not a clinical diagnosis.

Lower-volume neighbourhood around Lack of efficacy - Cytauxzoon feli

Lower-third volume poles plus nearest peers, not a full reaction corpus board reprint.

FDA AER report volume · neighbourhood around Lack of efficacy (protozoa) - Cytauxzoon feli

Lack of efficacy (protozoa) - Cytauxzoon feli: high death-coded share in the FDA AER plate

Signature read: Lack of efficacy (protozoa) - Cytauxzoon feli's 48.3% death-coded share is among the highest in the openFDA reaction corpus. Report volume is lower-third scale: 29 named reports in the openFDA extract. Death-coded share is upper-third: 14 of 29 reports (48.3% of named reports). Nearest volume peer: Application site moist eczema (±0 reports). Lead species Cat (29). Lead co-reported drug Fluralaner/Moxidectin Spot-On (10).

Read these counts as reporting volume, not risk: per our methodology, A high death-coded share in FDA filings does not prove causation; co-reporting is voluntary temporal association only. Browse the full reactions index or the about page for how PlainBreed frames FDA CVM extracts.

Species Most Affected

Cat 29

Breeds Most Affected

Domestic Shorthair 18

Domestic Mediumhair 4

Domestic Longhair 3

Cat (unknown) 3

American Shorthair 1

Associated Drugs

Fluralaner/Moxidectin Spot-On 10

Fluralaner Spot-On Solution 7

Eprinomectin + Esafoxolaner + Praziquantel 7

Selamectin;Sarolaner 5

Selamectin 1

What to do with this reaction

Read how death-coded share differs from a mortality rate before drawing conclusions. Understanding adverse events
Browse the full reaction directory to compare report counts across reaction types. All reactions

A report does not prove a drug caused the reaction; consult a veterinarian before acting on this data.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

openFDA Animal & Veterinary Adverse Events (FDA CVM) for Lack of efficacy (protozoa) - Cytauxzoon feli (#2015 of 2,481 by report volume); death-coded 48.3%. PlainBreed reaction plate · death-coded share stamp 48.3% · vintage 2025.

Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →